
51 - 200 employees
Founded 2015
π₯ Healthcare
π Manufacturing
𧬠Biotechnology
π° $201.2M Post-IPO Equity - Pharvaris on 2025-07
Healthcare β’ Manufacturing β’ Biotechnology
Pharvaris is a clinical-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency. The company aims to deliver injectable-like efficacy with a well-tolerated oral therapy and is advancing deucrictibant through pivotal Phase 3 trials for both prophylactic and on-demand treatment of HAE attacks. Pharvaris focuses on improving patient choice and quality of life by providing oral alternatives to injectable treatments.
π‘ We watch Pharvaris's careers page
Several times a day
how often we check
1
roles posted in the last 30 days
Selected: π Date Added.
π September 15
Care Specialist managing complex patient access, reimbursement, and adherence support for Pharvarisβ rare-disease therapies. Identifying barriers, escalating cases, and improving patient-services operations for U.S. launch readiness.
πΊπΈ United States β Remote
π΅ $110k - $150k / year
π° $201.2M Post-IPO Equity - Pharvaris on 2025-07
β° Full Time
π Senior
π΄ Lead
π» Ghost score 6%
π September 15
Patient Access Liaison helping U.S. patients and HCP offices navigate reimbursement and therapy access. Supporting Pharvarisβs commercial launch of bradykinin-mediated angioedema treatments.
πΊπΈ United States β Remote
π΅ $155k - $195k / year
π° $201.2M Post-IPO Equity - Pharvaris on 2025-07
β° Full Time
π Senior
π΄ Lead
β¨ Patient Access
π» Ghost score 6%